Comparison · NCT03904043-feee14cf
Radiation + FOLFOX vs Radiation + CAPOX: Clinical Complete Response Rate
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Radiation + FOLFOX vs Radiation + CAPOX: Clinical Complete Response Rate. Trial comparisons, record NCT03904043-feee14cf. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03904043-feee14cf
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.706 | 0.57 | 0.813 | wilson | |
| Risk in group 2 | 0.286 | 0.0822 | 0.641 | wilson | |
| Risk difference, group 1 minus group 2 | 0.42 | 0.0397 | 0.65 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.47 | 0.756 | 8.08 | log | |
| Odds ratio, group 1 over group 2 | 6 | 1.05 | 34.4 | log | |
| Number needed to treat, for one more participant with the outcome on Radiation + FOLFOX than on Radiation + CAPOX | 2.38 | 1.54 | 25.2 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Radiation + FOLFOX | * Pelvic radiotherapy 5GY x 5 fractions once daily~* Radiation to extra-mesorectal node 7 Gy x 5 fractions once daily~* FOLFOX should begin 2-4 weeks after completion of radiotherapy and will consist of FOLFOX x 8 cycles (16 weeks).~ * Oxaliplatin day 1 every 14 days~ * Leucovorin day 1 every 14 days. Levoleucovorin may be substituted if leucovorin is not available.~ * 5-FU bolus day 1 every 14 days~ * 5-FU infusion day 1 every 14 days over 46 hours~* An optional simultaneous integrated boost of 30 Gy in 5 fractions to the primary tumor is permitted | 36 | 51 | OG000 |
| Group 2 | Radiation + CAPOX | * Pelvic radiotherapy 5GY x 5 fractions once daily~* Radiation to extra-mesorectal node 7 Gy x 5 fractions once daily~* CAPOX should begin 2-4 weeks after completion of radiotherapy and will consist of CAPOX x 5 cycles (15 weeks).~ * Capecitabine 1000 mg/m\^2 by mouth twice per day on days 1-14 of every 21 day cycle~ * Oxaliplatin 130 mg/m\^2 intravenous on day 1 of each 21 day cycle~* An optional simultaneous integrated boost of 30 Gy in 5 fractions to the primary tumor is permitted | 2 | 7 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Clinical Complete Response Rate
- Description
\- Criteria for clinical complete response:~* No residual gross tumor at procto/sigmoidoscopy; or only erythematous scar or ulcer~* No palpable tumor on DRE~* No radiographic evidence of tumor on MRI~* No suspicious mesorectal lymph nodes on MRI~* Negative biopsy from scar, ulcer, or former tumor site (if necessary according to surgeon's judgment)
- Time frame
- Completion of treatment (estimated to be 22 weeks)
- Population
Source ClinicalTrials.gov
Trial
- Title
- Non-Operative Management and Early Response Assessment in Rectal Cancer
- NCT number
- NCT03904043
- Phases
- NA
- Conditions
- Adenocarcinoma of the Lower Rectum
- Interventions
- Radiation therapy, FOLFOX regimen, CAPOX regimen
- Lead sponsor
- Washington University School of Medicine
- Results first posted
- 2025-06-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03904043?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03904043-feee14cf